Repurposing antimicrobials, disulfiram, and metformin for cancer therapy: Bridging mechanistic gaps through RNA sequencing
European Journal of Pharmacology · 2025-11 · 1007 · 178258
DOI: 10.1016/j.ejphar.2025.178258 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Pharmacology, 2025-11. Verfasst von Siti Nazihahasma Hassan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, 16150, Malaysia; Hospital Pakar Universi…. Hauptthemen laut MEDLINE: Drug Repositioning, Metformin, Neoplasms, Disulfiram. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 215 Literaturangaben. Gefördert von: Universiti Sains Malaysia.
Abstract (Originalsprache)
This review focuses on antimicrobials (azithromycin, clarithromycin, clioquinol, chloroquine, doxycycline, erythromycin, ivermectin, and tigecycline), disulfiram, and metformin. It aims to highlight key knowledge gaps and the role of RNA sequencing in the translational repurposing of these agents for cancer therapy. Among the selected repurposed candidates, metformin is distinguished by an abundance of preclinical and clinical studies. Its anticancer activity is partly attributed to the induction of multiple regulated cell death pathways, including apoptosis, pyroptosis, necroptosis, and ferroptosis, alongside transcriptomic changes identified by bulk RNA sequencing across different cancer types. Clinical translation has thus far yielded mixed results, with drug-drug interactions, subtherapeutic concentrations, resistance mechanisms, and components of the tumour microenvironment representing key challenges to be addressed. In future, transcriptomics-guided drug repurposing, which enables patient stratification, together with the strategic use of repurposed agents informed by predictive biomarkers, may improve clinical outcomes. Bulk RNA sequencing provides a cost-effective means to assess drug-induced global gene expression changes, whilst single-cell and spatial transcriptomics offer finer resolution by capturing cell-type-specific responses and stromal influences, thereby enhancing precision in therapeutic targeting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, 16150, Malaysia; Hospital Pakar Universiti Sains Malaysia, Kubang Kerian, Kelantan, 16150, Malaysia.
- Department of Neurosciences, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, 16150, Malaysia; Hospital Pakar Universiti Sains Malaysia, Kubang Kerian, Kelantan, 16150, Malaysia. Electroni…
Förderung
- Universiti Sains Malaysia
Zitieren
APA
Hassan, S. N., & Ahmad, F. (2025). Repurposing antimicrobials, disulfiram, and metformin for cancer therapy: Bridging mechanistic gaps through RNA sequencing. European Journal of Pharmacology, 1007, 178258. https://doi.org/10.1016/j.ejphar.2025.178258
Vancouver
Hassan SN, Ahmad F. Repurposing antimicrobials, disulfiram, and metformin for cancer therapy: Bridging mechanistic gaps through RNA sequencing. European Journal of Pharmacology. 2025;1007:178258. doi:10.1016/j.ejphar.2025.178258
BibTeX
@article{Hassan2025,
author = {Hassan, Siti Nazihahasma and Ahmad, Farizan},
title = {Repurposing antimicrobials, disulfiram, and metformin for cancer therapy: Bridging mechanistic gaps through RNA sequencing},
journal = {European Journal of Pharmacology},
year = {2025},
volume = {1007},
pages = {178258},
doi = {10.1016/j.ejphar.2025.178258}
}
EUVIMED